InvestorsHub Logo

sox040713

05/25/16 12:58 AM

#148896 RE: KMBJN #148895

Thanks for reminding us about its bioavailability. With possible higher dosing and lower placebo rate, the next study should produce even better results.

Overall, the 200 mg results are very promising, and for sure room to go higher on the dosing, hopefully keeping the good side effect profile at higher doses.

lousy engineer

05/25/16 1:09 AM

#148897 RE: KMBJN #148895

Would the data good enough for the Prurisol asset to be monetized?? That's the question!

Hope big pharma likes the data, and we can monetize this asset now to fund our other trials.